Akoya Biosciences (AKYA) Scheduled to Post Quarterly Earnings on Monday

Akoya Biosciences (NASDAQ:AKYA) is set to issue its quarterly earnings data after the market closes on Monday, August 5th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter. Akoya Biosciences has set its FY 2024 guidance at EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Akoya Biosciences (NASDAQ:AKYA) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.05). Akoya Biosciences had a negative net margin of 72.68% and a negative return on equity of 111.80%. The company had revenue of $18.35 million during the quarter, compared to analyst estimates of $24.13 million. On average, analysts expect Akoya Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Akoya Biosciences Stock Down 4.3 %

Shares of AKYA opened at $2.22 on Friday. Akoya Biosciences has a 52 week low of $1.88 and a 52 week high of $6.88. The firm has a market cap of $109.65 million, a P/E ratio of -1.51 and a beta of 1.34. The firm’s 50-day simple moving average is $2.26 and its 200 day simple moving average is $3.79. The company has a debt-to-equity ratio of 2.33, a quick ratio of 2.38 and a current ratio of 3.07.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AKYA. Craig Hallum began coverage on shares of Akoya Biosciences in a research report on Friday, June 21st. They set a “buy” rating and a $7.50 target price on the stock. BTIG Research decreased their target price on shares of Akoya Biosciences from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, May 14th. Canaccord Genuity Group decreased their target price on shares of Akoya Biosciences from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, May 14th. Finally, Morgan Stanley decreased their target price on shares of Akoya Biosciences from $8.00 to $4.00 and set an “overweight” rating on the stock in a research report on Monday, June 3rd. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $7.25.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.